Business
Aeolus Announces Presentation of Pharmacometric Analysis of Data Establishing Optimal Dose Schedule of AEOL 10150 for Treatment of Lung Radiation Damage
Aeolus Announces Presentation of Pharmacometric Analysis of Data Establishing Optimal Dose Schedule of AEOL 10150 for Treatment of Lung Radiation Damage.
About this update from Aeolus Pharmaceuticals Inc
[{"type":"text","content":" AEOL 10150 treatment once per day for 60 days beginning 24 hours post-exposure: significantly improved survival at 180 Days delayed onset of lethal effects by 90 days Increased mean survival at 360 days Data presented at the American College of Clinical Pharmacology annual meeting in San DiegoMISSION VIEJO, CA / ACCESSWIRE / September 22, 2017 / Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced today presentation of pharmacometric-based analysis confirming the optimal dosing schedule for AEOL 10150 in the treatment of the pulmonary effects of acute radiation syndrome (\"Lung ARS\"). The analysis, performed by Jogarao Gobburu, PhD, Vijay Ivaturi, PhD and Hechuan Wang, MS with the Center for Translational Medicine, School of Pharmacy at the University of Maryland and funded by Aeolus' Lung ARS development contract with the Biomedical Advanced Research and Development Authority (\"BARDA\") confirmed that the significant improvement in survival and underlying pathophysiology seen in non-human primate (\"NHP\") efficacy studies was also seen in mouse studies. The conclusion of the analysis is that the optimal dose schedule based on results from studies in both species is AEOL 10150 administered for 60 days beginning 24 hours after exposure to lethal levels of radiation. The results of the analysis, \"Dose and Regimen Determination Study of AEOL10150 as a Mitigator of Radiation-Induced Lung Injury in C57L/J Mice,\" were presented at the American College of Clinical Pharmacology annual meeting in San Diego.\"The pharmacometric modeling of AEOL 10150's effects in treating the pulmonary effects of acute radiation exposure is compelling and our modeling and analysis of the data from multiple studies conducted in the mouse and NHP models clearly shows that treatment for 60 days beginning 24 hours after exposure produces optimal and statistically significant survival benefits,\" stated Jogarao Gobburu, PhD, Executive Director of the Center for Translational Medicine, Schools of Pharmacy and Medicine at the University of Maryland. \"In addition to the statistically significant survival seen for the primary endpoint of 180 day survival, treatment with AEOL 10150 for 60 days delays the onset of lethal effects of radiation exp...